SecBot SecBot
SECBOTREPLAY Home › Report › NRXP

NRXP · NRx Pharmaceuticals announced that the FDA reclassified its ANDA…

NRX Pharmaceuticals, Inc. · 8-K filed Sep 15, 2026 at 21:17 ET

At the news

BULLISHIMPACT 5/10

8-K filed Sep 15, 2026 at 21:17 ET

NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ketamine (NRX-100) from a Major Amendment to a Minor Amendment, pulling the GDUFA goal date forward to November 10, 2026. This regulatory de-escalation signals a lower review burden and accelerates the timeline toward potential approval of a drug-shortage product, a modest but positive catalyst for a clinical-stage biopharma with a $147M market cap.

  • FDA reclassified NRx's ANDA amendment from Major to Minor Amendment.
  • GDUFA goal date revised to November 10, 2026.
  • FDA cited the reclassified amendment will not require a substantial expenditure of resources.
  • Product is preservative-free ketamine (NRX-100), designated a drug shortage product.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access